---
category: news
title: "CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation"
excerpt: "CRISPR Therapeutics AG CRSP announced that its wholly-owned allogeneic CAR-T cell therapy, CTX110, targeting CD19+ B-cell malignancies, has been granted Regenerative Medicine Advanced Therapy (“RMAT”) designation by the FDA."
publishedDateTime: 2021-11-23T16:01:00Z
originalUrl: "https://www.nasdaq.com/articles/crisprs-crsp-car-t-cell-therapy-gets-fdas-rmat-designation"
webUrl: "https://www.nasdaq.com/articles/crisprs-crsp-car-t-cell-therapy-gets-fdas-rmat-designation"
ampWebUrl: "https://www.nasdaq.com/articles/crisprs-crsp-car-t-cell-therapy-gets-fdas-rmat-designation?amp"
cdnAmpWebUrl: "https://www-nasdaq-com.cdn.ampproject.org/c/s/www.nasdaq.com/articles/crisprs-crsp-car-t-cell-therapy-gets-fdas-rmat-designation?amp"
type: article
quality: 69
heat: 69
published: false

provider:
  name: Nasdaq
  domain: nasdaq.com

topics:
  - AI in Healthcare
  - AI

secured: "hDL6chBsNIC2xTWh1L3vN8WHt3h+03UHoMOgQZvhXBXUUOiUIw5TkfSalEE4RLvcCRs3wo/Vf+BBJYtYm4cwfeMpZT7agX/NM+r6Q/e4Tkcg8LGZwQmzDB2q/VZV75UxSR+bqof/+TpypcT326NyLYAJ4ucRl9utc35eup/szDxGKPzgSUAQBY+fZH3nugsS6OXFR0Iuc2EYy5Ch7MUzVqRb9MYx8A50J3H99sxDkTqZ/NkKQZd/xng8zJkIYZGCqn1ExzYc0KqtTjbalkZTdgpDFkQ8fKQ6jJXuLzVuCVs3hwUzP5x6FRRQ+U1B4vVCuo6xf0PgZtHwBqM9PXTYKntm8eZUEA0VD2emimANvEw=;bzorpmkZLBAF80hXRXVe/w=="
---

